• World’s first innovative drug for treatment of lung cancer.
  • It took Cadila Pharmaceuticals over a decade, a huge investment and dedicated team work from its Research and Development set up to develop this unique drug·          
  • As per WHO report, approximately, 1.25 million people are diagnosed with lung cancer every year worldwide

November 21, 2013 I Cadila Pharmaceuticals Limited, one of India’s largest privately held pharmaceuticals company, has launched for the first time in the world, Mycidac-C, an affordable, unique and innovative drug for the treatment of Lung Cancer.

Mycidac-C is an innovative research product for the patients suffering from Non Small Cell Lung Cancer (NSCLC). The drug has been approved for launch in India by the Drug Controller General of India (DCGI). It targets Desmocolin-3, a novel target.

This is a first in the class active immunotherapy as well as drug targeting Desmocollin-3. It is a breakthrough in the management of squamous cell NSCLC. There has been no significant innovation in management of squamous NSCLC since the introduction of platinum containing doublet in 1983. Besides affordability and other advantages, Mycidac-C has no systemic side effects during the treatment. Mycidac-C is to be used with platinum containing doublet therapy.

As per the World Health Organisation (WHO) report, approximately 1.25 million people are diagnosed with lung cancer every year worldwide. Around 30% of them suffer from squamous NSCLC. Lung Cancer kills more people than the three next commonest cancers combined.

This is in line with the vision of Shri I A Modi, Founder Chairman, Cadila Pharmaceuticals Ltd., to make affordable healthcare accessible to the masses for alleviating human suffering. Mycidac-C can be administered easily by trained paramedics, thus further reducing the cost of hospitalisation associated with other cancer therapy.

Speaking at the launch, Dr Rajiv I Modi, Chairman and Managing Director of Cadila Pharmaceuticals said, “It has taken us over a decade, a huge investment and a dedicated research and development team to develop this unique drug. We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years.”

Dr T. Ramasami, Secretary to the Government of India, Department of Science and Technology also commented: “Lung cancer is a major killer among all cancers. In this scenario, Mycidac-C is a new hope for the patients suffering form lung cancer, particularly for Indian patients.”

About Cadila Pharmaceuticals www.cadilapharma.com

With a turnover of Rs 1200 crore, Cadila Pharmaceuticals Limited is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, Gujarat. Over the last six decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, anti-diabetics and immunologicals. It has more than seven thousand employees across the globe.

Cadila Pharmaceuticals was the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed 5 INDs with the USFDA.

SOURCE: Cadila Pharmaceuticals